Otelast

Apremilast
- (Immunosuppressants)

Indication:
Apremilast, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:

  • Adult patients with active psoriatic arthritis
  • Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Dosage & Administration:
Dosage in Psoriatic Arthritis and Psoriasis

The recommended initial dosage titration of Apremilast from Day 1 to Day 5 is shown in Table 1. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the

 AMPM
Day 110 mg-
Day 210 mg10 mg
Day 310 mg20 mg
Day 420 mg20 mg
Day 520 mg30 mg
Day 6 & thereafter30 mg30 mg

gastrointestinal symptoms associated with initial therapy.

Apremilast can be administered without regard to meals. Do not crush, split, or chew the tablets.

Table 1: Dosage Titration Schedule

Dosage Adjustment in Patients with Severe Renal Impairment

Apremilast dosage should be reduced to 30 mg once daily in patients with severe renal impairment (creatinine clearance (CLcr) of less than 30 mL per minute estimated by the Cockcroft–Gault equation).

For initial dosage titration in this group, it is recommended that Apremilast be titrated using only the AM schedule listed in Table 1 and the PM doses be skipped.

Preparation:
Otelast 10: Each box contains 20 tablets in alu-alu blister pack.
Otelast 30: Each box contains 20 tablets in alu-alu blister pack.



  • Products By Trade Name

  • Products By Generic

  • Products By Therapeutic Class

  • Herbal & Nutraceuticals

  • AgroVet & Pesticides